Trial Profile
A Phase I Study of the Safety and Feasibility of Azacitidine After Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Stem Cell Transplantation.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Sep 2015
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Acute myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
- Focus Adverse reactions
- 12 Aug 2013 Planned number of patients changed from 20 to 21 as reported by ClinicalTrials.gov.
- 01 Mar 2013 Planned end date changed from 1 Jun 2013 to 1 Oct 2015 as reported by ClinicalTrials.gov.
- 19 Jul 2012 Planned end date changed from 1 Apr 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.